Imbed Biosciences

About Imbed Biosciences

Imbed Biosciences is a privately held medical device company based in Middleton, Wisconsin, developing next-generation wound care products through its proprietary SAM™ (Synthetic Antimicrobial Matrix) technology platform. The company's core innovation lies in integrating multiple therapeutic agents — including antimicrobial silver and, more recently, lidocaine HCl for localized pain management — into ultra-thin, fully synthetic, bioresorbable fiber matrices. These matrices are engineered to reduce bioburden, suppress biofilm formation, and promote skin regeneration, targeting both chronic and acute wound indications. Its commercial portfolio includes Microlyte® (for chronic wounds such as ulcers), Pelashield™ (burn and acute wound care), and Surgaflex™ (surgical and acute wounds), each also available in PainGuard™ variants that combine antimicrobial action with non-opioid pain relief via lidocaine HCl. The company is FDA-registered as a medical device manufacturer and ISO 13485:2016 certified, with products cleared for indications spanning ulcers, burns, traumatic wounds, and surgical wounds. Imbed also has an active pipeline, including a silver-gallium matrix technology that received FDA Investigational Device Exemption (IDE) approval for clinical trials. The company additionally markets veterinary wound care products under the MicroLyte® Vet brand. Imbed serves healthcare professionals including physicians, surgeons, and wound care specialists, primarily in hospital and outpatient clinic settings, as well as the veterinary market. The global advanced wound care market, estimated to be worth tens of billions of dollars annually, faces growing challenges from antibiotic resistance and chronic wound prevalence — conditions Imbed's fully synthetic, antibiotic-free approach directly addresses.